GlassScriptPhysician profile
Samuel A Nix
NPI 1780075473
$5,625.77
in general payments reported to CMS, 2019-2025
30 companies · $1,485 in 2025
The $1,485 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $430 · 2022: $1,044 · 2023: $1,591 · 2024: $1,075 · 2025: $1,485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,151.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $681.78 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Novo Nordisk INC | $679.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $677.08 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.56 | 2022-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $217.11 | 2022-2024 | Rexulti, Abilify Maintena |
| Pfizer INC. | $205.06 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $195.33 | 2022-2024 | Quviviq |
| Evoke Pharma, INC. | $176.22 | 2024-2025 | |
| Astellas Pharma US INC | $173.89 | 2023-2024 | Veozah, Myrbetriq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.49 | 2022-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $154.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.62 | 2021-2024 | Trintellix |
| Glaxosmithkline, LLC. | $84.66 | 2022-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $77.79 | 2024 | Gvoke Hypopen |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $70.71 | 2023-2025 | Auvelity, Sunosi |
| Sanofi-Aventis U.S. LLC | $58.60 | 2021-2024 | |
| Abbott Laboratories | $50.74 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $50.62 | 2025 | Otezla, Repatha |
| Boston Scientific Corporation | $48.24 | 2025 | General - Therapies, Infinion 16 |
| Dexcom, INC. | $47.92 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $37.34 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $23.21 | 2023 | Vivitrol |
| Almatica Pharma LLC | $20.18 | 2024 | Loreev Xr |
| Lundbeck LLC | $20.03 | 2023 | Vyepti |
| Avion Pharmaceuticals | $19.94 | 2023 | NP Thyroid 60 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.16 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.07 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $13.74 | 2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $13.14 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Nix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.